Madagascar

Population 2017  26 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2017</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>13 (7.8–20)</td>
<td>52 (31–79)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.65 (0.29–1.2)</td>
<td>2.6 (1.1–4.5)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>61 (39–87)</td>
<td>238 (154–340)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>1.5 (0.69–2.7)</td>
<td>6 (2.7–11)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>0.44 (0.087–1.1)</td>
<td>1.7 (0.34–4.2)</td>
</tr>
</tbody>
</table>

Estimated TB incidence by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th>0-14 years</th>
<th>&gt; 14 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>3.7 (3.4–4.1)</td>
<td>19 (15–24)</td>
</tr>
<tr>
<td>Males</td>
<td>4.1 (3.7–4.6)</td>
<td>33 (24–43)</td>
</tr>
<tr>
<td>Total</td>
<td>7.9 (6.8–9)</td>
<td>53 (34–72)</td>
</tr>
</tbody>
</table>

TB case notifications, 2017

- % tested with rapid diagnostics at time of diagnosis
  - % with known HIV status 50%
  - % pulmonary 80%
  - % bacteriologically confirmed among pulmonary 87%

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2017 52% (36–80)
- TB/HIV care in new and relapse TB patients, 2017
  - Patients with known HIV-status who are HIV-positive 156 <1%
  - on antiretroviral therapy 70 45%

Drug-resistant TB care, 2017

- Estimated MDR/RR-TB cases among notified pulmonary TB cases 250 (13–490)
- Estimated % of TB cases with MDR/RR-TB 0.49% (0.09–1.2) 5.9% (0.59–17)
- % notified tested for rifampicin resistance 0% 28% 612
- MDR/RR-TB cases tested for resistance to second-line drugs 17
- Laboratory-confirmed cases MDR/RR-TB: 30, XDR-TB: 0
- Patients started on treatment **** MDR/RR-TB: 18, XDR-TB: 0

Treatment success rate and cohort size

- New cases registered in 2016 84% 27 818
- Previously treated cases registered in 2016 79% 2 120
- HIV-positive TB cases registered in 2016 0
- MDR/RR-TB cases started on second-line treatment in 2015 57% 7
- XDR-TB cases started on second-line treatment in 2015 0

TB preventive treatment, 2017

- % of HIV-positive people (newly enrolled in care) on preventive treatment 9%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 23% (21–25)

TB financing, 2018

- National TB budget (US$ millions) 2.7

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2018-09-21